A complication of acute respiratory distress syndrome is being developed in a group of patients and these patients were hospitalized. Investigators have successfully found a proper cure for it and the treatment which includes an immune receptor blocker in combination with an antiviral agent and this agent improves the chances of survival in mice who are highly infected with lethal influenza and successfully reduces lung pathology in swine influenza-infected piglets. This should be very effective in the case of humans as well. This research was done with great expertise and professors from highly domain industries. This research also provides insights into the optimal timing of treatment to prevent acute lung injury. Lung injury is a very harmful disease and there is a high risk of death involved. The research was published in the journal of pathology which is actively published by Elsevier and investigators have found that treatment with an immune receptor blocker in combination with an antiviral agent. In the past few years, the investigators found that an excessive influx of neutrophils infection-fighting immune cells and the path that is made by them to end pathogens are called neutrophil extracellular traps which are responsible for exact lung injury risk when there is influenza infection.
It is being seen that formation of NETs happens by a specific function and process and when neutrophils are activated it occurs via a mechanism and that mechanism takes place due to a dead cell called NETossis. The released NETs carry chromatin fibers that become toxic components and which are very harmful and make a lot of complications. Influenza is highly explored by the mouse model and the drugs and pathophysiology are used by the researchers in the current study.
Since mice are not considered natural hosts for influenza, further validation in larger animals is necessary before testing in humans. Therefore, researchers also tested piglets infected with the swine influenza virus. The animals were treated with a combination of a CXCR2 antagonist, SCH527123, together with an antiviral agent, oseltamivir. The combination of SCH527123 and oseltamivir significantly improved survival in mice compared to either of the drugs administered alone. The combination therapy also reduced pulmonary pathology in piglets. Combination therapy reduces lung inflammation, alveolitis, and vascular pathology, indicating that aberrant neutrophil activation and release in NETs exacerbate pulmonary pathology in severe influenza.
